COMMUNICATION:
Synaptojanin Is the Major Constitutively Active Phosphatidylinositol-3,4,5-trisphosphate 5-Phosphatase in Rodent Brain*

(Received for publication, January 14, 1997)

Rüdiger Woscholski Dagger , Peter M. Finan Dagger §, Elizabeth Radley Dagger , Nicholas F. Totty , Alistair E. Sterling , J. Justin Hsuan par , Mike D. Waterfield par and Peter J. Parker Dagger **

From the Dagger  Protein Phosphorylation Laboratory, Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, § Yamanouchi Research Institute, Littlemore Park, Oxford, OX4 4SX,  Ludwig Institute for Cancer Research, 91 Riding House Street, London, W1P 8BT, and par  Department of Biochemistry and Molecular Biology, University College, Gower Street, London WC1E 6BT, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

The major constitutive phosphatidylinositol-3,4,5-P3 (PtdIns) 5-phosphatase activity was purified and subjected to peptide sequence analysis providing extensive amino acid sequence which was subsequently used for cloning the cDNA. Peptide and cDNA sequences revealed that the purified PtdIns(3,4,5)P3 5-phosphatase was identical to a splice variant of a recently cloned inositol polyphosphate 5-phosphatase termed synaptojanin. Since synaptojanin is not known to possess PtdIns(3,4,5)P3 5-phosphatase activity, we verified that the purified PtdIns(3,4,5)P3 5-phosphatase activity and synaptojanin are identical by Western blot using specific antibodies raised against synaptojanin sequences. Immunoprecipitation from crude lysates of rat brain tissue showed that synaptojanin accounts for the major part of the active PtdIns(3,4,5)P3 5-phosphatase activity. It is also shown that the protein is localized to the soluble fraction. Expression of a truncated recombinant protein demonstrates that the conserved 5-phosphatase region of the synaptojanin gene expresses PtdIns(3,4,5)P3 5-phosphatase activity. However, immunological analysis demonstrates that the PtdIns(3,4,5)P3 5-phosphatase activity expressed from the synaptojanin gene in brain is due to a particular splice variant which contains a 16-amino acid insert as shown by immunoprecipitation using a specific antibody raised against this particular splice variant.


INTRODUCTION

The regulation of inositol phospholipid metabolism has provided a cornerstone to at least two signal transduction pathways, one involving the phospholipase C-dependent phosphodiesterase cleavage of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2)1 (1) and the second the phosphorylation of this lipid by PtdIns 3-kinases yielding PtdIns(3,4,5)P3 (2, 3). This latter lipid second messenger has been implicated in a number of signaling pathways (PKB/akt, p70S6k, PKC, PRK) as has its metabolite PtdIns(3,4)P2 (4-9). It has been suggested that the 5-phosphatase responsible for the transformation of PtdIns(3,4,5)P3 to PtdIns(3,4)P2 (10) is due to a recently cloned 5-phosphatase termed SIP (11) or SHIP (p145SHIP) (12-14) which has specificity for 3-phosphorylated inositol phosphates (11-14). However, other PtdIns(3,4,5)P3 5-phosphatases have been identified (15, 16) indicating that this issue is still not resolved.

We have previously identified and purified the major constitutive PtdIns(3,4,5)P3 5-phosphatase from rodent brain tissue (16). Here we demonstrate that this protein is encoded by a particular splice variant of the recently described synaptojanin gene. It is further shown that a recombinant synaptojanin protein has intrinsic PtdIns(3,4,5)P3 5-phosphatase activity. Thus, we are able to show that synaptojanin which to date has not been associated with PtdIns 3-kinase signaling could play a major role in PtdIns 3-kinase-dependent pathways.


EXPERIMENTAL PROCEDURES

Microsequencing of Purified Rat Brain PIP3 5-Phosphatase

The 5-phosphatase was purified (16), further fractionated by SDS-polyacrylamide gel electrophoresis, and stained with Coomassie Brilliant Blue R250. The bands were excised and digested with lysyl endopeptidase (Wako Chemicals) or with endoproteinase Asp-N (Boehringer Mannheim). Peptides were extracted for 2 h in a sonicating water bath. After concentration the peptides were resolved using an Aquapore AX-300 (30 × 2.1 mm) and OD-300 (150 × 2.1 mm) columns connected in series on a Hewlett-Packard 1090M high performance liquid chromatography system. The columns were developed with a linear acetonitrile gradient in 0.1% trifluoroacetic acid. Peptide elution was monitored by means of diode-array detection (200-600 nm). Peptides were sequenced using an ABI 494 HT Procise sequencer employing fast cycles as described previously (17). Initial yields were in the 2-10-pmol range.

Expression of Synaptojanin Constructs in COS7 Cells

Details of the cloning of the PIP3 5-phosphatase will described elsewhere. Briefly, primers were designed based on the obtained peptide sequence and then used to amplify the corresponding cDNA sequence using the polymerase chain reaction (PCR) from a rat brain library (Stratagene). The cDNA produced was then used as a probe to search for PIP3 5-phosphatase clones.

For expression of the PIP3 5-phosphatase in COS7 cells, a cDNA encoding residues 401-1308 (Syn N-del; including the 16-amino acid insert (18)) and residues 401-989 (Syn core; excluding C terminus and splice insert) of synaptojanin were amplified by PCR from the isolated cDNA clone using oligonucleotides containing an EcoRI site (5' oligonucleotide) and XhoI site (3' oligonucleotide). An EcoRI-XhoI-digested PCR fragment was subcloned into a pCDNA3 derivative which had been modified to contain a myc epitope (MEQKLISEEDL) followed by an in-frame EcoRI site. Expression of the myc-tagged protein was driven from a cytomegalovirus promoter. The correct sequence of the myc-tagged phosphatase construct was confirmed by DNA sequence analysis. COS7 cells were transfected by electroporation.

Immunoprecipitation and Phosphatase Assay

Antibodies were raised against the C terminus of synaptojanin (C-term) or the unique splice sequence "GVGAPPSPGVTRREME"(insert) in rabbits. The corresponding peptide antigen was included in immunoprecipitation experiments or Western blots as a control. Antibodies raised against the unique insert region (insert), the C terminus (C-term), or the myc epitope were bound to protein A beads. Antibody-loaded beads were then incubated for 3 h with rat brain fractions at 4 °C. The supernatant was separated by centrifugation, and the beads were washed several times using phosphate-buffered saline and phosphate-buffered saline containing 0.5 M NaCl. Supernatant and washed beads were then assayed for PtdInsP3 5-phosphatase activity as described (16). For Western blots, the extracts were subjected to SDS-gel electrophoresis transferred onto PVDF or nitrocellulose membranes and incubated with the indicated antibodies. Proteins were visualized by ECL (Amersham). All other methods were done as described previously (16).


RESULTS

The 145-kDa protein previously purified and identified as a PtdIns(3,4,5)P3 5-phosphatase was subjected to proteolytic fragmentation and amino acid sequence analysis. A total of 23 peptide sequences covering 361 amino acids were determined (not shown). During the course of the cDNA cloning of this protein, the sequence of synaptojanin was reported (18), and it became clear that the 145-kDa protein sequenced was in fact a particular splice variant of synaptojanin containing a defined 16-amino acid insert (see Fig. 1). For simplicity the purified protein will be termed hereafter p145Isynj (145-kDa species of synaptojanin containing the 16-amino acid insert); the insertless protein is denoted p145synj.


Fig. 1. The purified PtdInsP3 5-phosphatase is identical to synaptojanin. The purified PtdInsP3 5-phosphatase (16) was subjected to Edman microsequencing using Asp-N and Lys-C digests. The determined peptide sequences (light gray and black boxes) are aligned with the synaptojanin sequence (18) (shown in white). Synaptojanin consists of at least two forms due to splicing which inserts a short peptide sequence (GVGAPPSPGVTRREME) in the C-terminal part of the protein (black box). Sequences which were used as antigens for antibody production are shown as black boxes; these had also been identified by Edman microsequencing.
[View Larger Version of this Image (9K GIF file)]


Synaptojanin is a component of synaptic vesicles and is thought to play a key role in vesicle traffic at the synapse (18). PtdIns 3-kinase activities are themselves implicated in vesicle traffic in non-neuronal cells. For example by analogy to the Saccharomyces cerevisiae VPS34 gene product, which is a PtdIns-specific PtdIns 3-kinase, the mammalian homologue is likely to play a role in trans-Golgi to lysosome traffic (19, 20). There is also circumstantial evidence for PtdIns(4,5)P2 3-kinase activities controlling endosome fusion (21-23) as well as traffic of the Glut4 transporter to the cell surface (24, 25). In this context, functional identity of the synaptosomal protein synaptojanin is a key issue. However, PtdIns(3,4,5)P3 5-phosphatase activity has not been found associated with synaptojanin (18); thus it has been important to establish this identity.

To define the function of synaptojanin, specific antisera were derived. The antisera to p145Isynj as well as to the C terminus common to both forms p145Isynj and p145synj were found to react with the purified rodent brain 5-phosphatase, confirming the presence of p145Isynj (Fig. 2). It is noteworthy that the common antiserum did not reveal any additional protein species.


Fig. 2. The purified PtdInsP3 5-phosphatase is recognized by antibodies against synaptojanin. The purified PtdInsP3 5-phosphatase (16) was subjected to SDS-polyacrylamide gel electrophoresis and transferred onto a PVDF membrane (Western blot). The PVDF membrane was then incubated with insert and C terminus antibodies in the presence (+) or absence (-) of the corresponding peptide antigen. The position of the 145-kDa band (PtdInsP3 5-phosphatase) is indicated by an arrow.
[View Larger Version of this Image (26K GIF file)]


These synaptojanin-specific sera can be shown to immunodeplete the p145Isynj protein from crude rodent brain extracts, and this correlates with depletion of PtdIns(3,4,5)P3 5-phosphatase activity (Fig. 3). Thus, immunoprecipitation with the insert-specific antiserum depleted >90% of the PtdIns(3,4,5)P3 5-phosphatase activity from rat brain extracts. This depletion was specific, since inclusion of the peptide antigen fully competed the activity depletion. Immunoprecipitates with these antisera demonstrated recovery of 5-phosphatase activity, and this was also specific as demonstrated by antigen competition (Fig. 3, panel A).


Fig. 3. Antibodies against synaptojanin immunoprecipitate PtdInsP3 5-phosphatase activity from rat brain cytosol. Rat brain cytosol and membrane fractions were prepared as described earlier (16). A, antibodies raised against the unique insert region (insert) and the C terminus (C-term.) were bound to protein A beads. For comparison, protein A beads were loaded with a bovine IgG fraction (control). Antibody-loaded beads were then incubated for 3 h with rat brain cytosol at 4 °C in the presence (+) or absence (-) of competing peptide antigen. The supernatants were separated by centrifugation, and the beads were washed and then assayed for PtdInsP3 5-phosphatase activity as described (16). The autoradiograph of a thin layer chromatography separation of the lipid products of the phosphatase assay is shown; the position of the phosphoinositides are indicated by arrows. B, aliquots of the supernatants from the immunoprecipitation experiment (see panel A) were separated by SDS-polyacrylamide gel electrophoresis and transferred onto PVDF membranes (Western blot). The membranes were incubated with insert or C terminus antibodies. The position of the 145-kDa band is indicated. C, the subcellular fractions, i.e. crude extract (E), cytosol (C), and membrane (M), were subjected to SDS-polyacrylamide gel electrophoresis and then transferred onto PVDF membranes (Western blot). The PVDF membranes were then incubated with antibodies raised against synaptojanin (insert or C terminus) as described above (see Fig. 2). The position of the 145-kDa band (synaptojanin) and the presence (+) of competing antigen peptide are indicated.
[View Larger Version of this Image (19K GIF file)]


The antiserum to the C terminus common to both p145synj and p145Isynj also immunoprecipitated 5-phosphatase activity albeit less efficiently than the insert sera. Western analysis of extracts subjected to immunoprecipitation confirmed the depletion of p145Isynj (see Fig. 3B) and also demonstrates that there is very little p145synj expressed (the insert-specific antiserum almost fully depletes p145synj immunoreactivity). Consistent with the incomplete immunoprecipitation of the 5-phosphatase activity, the C-terminal antiserum only partially depletes the antigen.

Fractionation of brain extracts was performed to establish the distribution of p145synj and p145Isynj. Consistent with our previous analysis of PtdIns(3,4,5)P3 5-phosphatase activity distribution, on hypotonic extraction, p145Isynj is found to be predominantly cytosolic with little immunoreactive protein detected on the membrane (see Fig. 3C).

To establish that the synaptojanin gene encodes a protein with intrinsic PtdIns(3,4,5)P3 5-phosphatase activity, an N-terminally deleted expression construct was prepared that included the predicted catalytic domain of the protein (see Fig. 4). Transient expression in COS cells correlates with the production of a protein that was immunoreactive with p145Isynj antisera (panel A). Activity determination demonstrated that this protein had PtdIns(3,4,5)P3 5-phosphatase activity (panel B). Similar observations have been made for a C-terminal deletion that does not encode the splice insert (data not shown).


Fig. 4. A synaptojanin construct expressed in COS cells has PtdInsP3 5-phosphatase activity. Cells were harvested 48 h after transfection. The cells were lysed either in SDS-polyacrylamide gel electrophoresis sample buffer (for Western blot) or 1% Triton X-100 in Tris-buffered saline (for immunoprecipitation). A, SDS extracts of COS cells expressing empty vector (vector), the myc-tagged 5-phosphatase core domain not containing the splice insert (Syn core), or a myc-tagged N-terminal truncated form (Syn N-del) were subjected to gel electrophoresis and transferred onto nitrocellulose. Western blots were performed as described in the legends to Figs. 2 and 3 except using the anti-myc monoclonal antibody 9E10 and an antimouse horseradish peroxidase second antibody. B, Triton extracts of the COS cells expressing 5-phosphatase constructs (see above) were subjected to immunoprecipitation using the anti-myc monoclonal antibody 9E10 coupled to protein A beads, and the washed immunoprecipitates were assayed for PtdInsP3 5-phosphatase activity as described in Fig. 3.
[View Larger Version of this Image (13K GIF file)]



DISCUSSION

The results presented here demonstrate that p145Isynj has intrinsic PtdIns(3,4,5)P3 5-phosphatase activity. The immunodepletion of PtdIns(3,4,5)P3 5-phosphatase activity, alongside that of p145Isynj protein shows that in fact this protein represents the major constitutive activity expressed in brain tissue. The expression of recombinant proteins encompassing the catalytic domain (with or without the splice insert) indicates that all the known splice variants from this gene would retain PtdIns(3,4,5)P3 5-phosphatase activity. However, the p145Isynj variant itself appears to be the major form present in brain based upon the immunodepletion data. This conclusion is entirely consistent with the purification of this activity from rat brain, since only a single peak of constitutive activity was observed (16), and as shown here this activity purified to near homogeneity after SDS-polyacrylamide gel electrophoresis yielding p145Isynj.

The properties of the native purified 5-phosphatase protein have been characterized and provide evidence of a much higher affinity for PtdIns(3,4,5)P3 over PtdIns(4,5)P2. Indeed the protein was purified on the basis of activity determined against 32P-labeled PtdIns(3,4,5)P3 in the presence of an ~10-fold excess of unlabeled PtdIns(4,5)P2 (16). This relative preference for PtdIns(3,4,5)P3 contrasts with the related p145SHIP (12-14) which has been reported to be devoid of 5-phosphatase activity toward PtdIns(4,5)P2 and the 43-kDa inositol polyphosphate 5-phosphatase which does not hydrolyze inositol lipids (26, 27). Interestingly p145SHIP itself has poor activity toward PtdIns(3,4,5)P3 compared with the 75-kDa type II phosphatase (11, 15). The molecular basis for these distinctions must await structural analysis.

The PtdIns(3,4,5)P3 5-phosphatase activity of synaptojanin implicates the complex regulation of PtdIns(4,5)P2-PtdIns(3,4,5)P3-PtdIns(3,4)P2 inositol lipid metabolism in the directional cycle of events required for neurotransmitter granule recycling in the synapse. However it is clear that both p145Isynj and p145synj are largely cytosolic in brain extracts although there is a higher proportion of synaptojanin in the particulate fraction of synaptosomes (data not shown) which is in agreement with recent studies (28). Hence, a dynamic interaction of synaptojanin with the membrane has to be proposed. Such behavior would be compatible with many other "membrane-interacting" proteins (e.g. protein kinase C (29)) and "membrane-metabolizing" proteins (e.g. PtdIns-phospholipase C (30)) involved in regulatory processes. The ability of amphiphysin to interact with synaptojanin and so tether it to neurotransmitter granules may be a crucial element in the protein's role (18).

The involvement of 3-phosphorylated polyphosphoinositides in vesicle traffic processes in mammalian cells has been implied through the use of the fungal metabolite wortmannin (5, 22, 31) which is a potent inhibitor of a number of the phosphoinositide 3-kinases (32, 33). However, the specific role of PtdIns(3,4,5)P3 is unknown in this context. Indeed it is not clear whether PtdIns(3,4,5)P3 or actually PtdIns(3,4)P2 is the key element. The identification of p145Isynj as a PtdIns(3,4,5)P3 5-phosphatase provides evidence that in neuronal cells the metabolism of PtdIns(3,4,5)P3 in granules or following fusion at synaptic termini is a critical component in their cycling. Whether this is a part of the cycling itself, for example by marking the vesicle at one stage in its cycle, or whether this is simply a negative regulatory device to effectively remove PtdIns(3,4,5)P3 from the vesicle remains to be determined.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
**   To whom correspondence should be addressed: Protein Phosphorylation Laboratory, Imperial Cancer Research Fund, P. O. Box 123, Lincoln's Inn Fields, London WC2A 3PX, UK. Tel.: 44-171-269-3460; Fax: 44-171-269-3092.
1   The abbreviations used are: PtdIns, phosphatidylinositol; PIP3, phosphatidylinositol 3,4,5-trisphosphate; PCR, polymerase chain reaction; PVDF, polyvinylidene difluoride.

ACKNOWLEDGEMENTS

We thank Drs. N. Q. McDonald and A. E. Stewart for helpful discussions. We are also grateful to Drs. D. Nicholls and J. Ryves for synaptosome preparations.


REFERENCES

  1. Noh, D. Y., Shin, S. H., and Rhee, S. G. (1995) Biochim. Biophys. Acta 1242, 99-113 [CrossRef][Medline] [Order article via Infotrieve]
  2. Stephens, L. R., Jackson, T. R., and Hawkins, P. T. (1993) Biochim. Biophys. Acta 1179, 27-75 [Medline] [Order article via Infotrieve]
  3. Carpenter, C. L., and Cantley, L. C. (1996) Biochim. Biophys. Acta 1288, M11-M16 [CrossRef][Medline] [Order article via Infotrieve]
  4. Burgering, B. M. T., and Coffer, P. J. (1995) Nature 376, 599-602 [CrossRef][Medline] [Order article via Infotrieve]
  5. De Camilli, P., Emr, S. D., McPherson, P. S., and Novick, P. (1996) Science 271, 1533-1539 [Abstract]
  6. MacDougall, L. K., Domin, J., and Waterfield, M. D. (1995) Curr. Biol. 5, 1404-1415 [Medline] [Order article via Infotrieve]
  7. Palmer, R. H., Dekker, L. V., Woscholski, R., Le Good, A., Gigg, R., and Parker, P. J. (1995) J. Biol. Chem. 270, 22412-22416 [Abstract/Free Full Text]
  8. Pearson, R. B., Dennis, P. B., Han, J. W., Williamson, N. A., Kozma, S. C., Wettenhall, R. E. H., and Thomas, G. (1995) EMBO J. 14, 5279-5287 [Abstract]
  9. Toker, A., Meyer, M., Reddy, K. K., Falck, J. R., Aneja, R., Aneja, S., Parra, A., Burns, D. J., Ballas, L. M., and Cantley, L. C. (1994) J. Biol. Chem. 269, 32358-32367 [Abstract/Free Full Text]
  10. Stephens, L. R., Hughes, K. T., and Irvine, R. F. (1991) Nature 351, 33-39 [CrossRef][Medline] [Order article via Infotrieve]
  11. Kavanaugh, W. M., Pot, D. A., Chin, S. M., Deuter-Reinhard, M., Jefferson, A. B., Norris, F. A., Masiarz, F. R., Cousens, L. S., Majerus, P. W., and Williams, L. T. (1996) Curr. Biol. 6, 438-445 [Medline] [Order article via Infotrieve]
  12. Damen, J. E., Liu, L., Rosten, P., Humphries, R. K., Jefferson, A. B., Majerus, P. W., and Krystal, G. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1689-1693 [Abstract/Free Full Text]
  13. Lioubin, M. N., Algate, P. A., Schickwann, T., Carlberg, K., Aebersold, R., and Rohrschneider, L. R. (1996) Genes Dev. 10, 1084-1095 [Abstract]
  14. Drayer, A. L., Pesesse, X., De Smedt, F., Woscholski, R., Parker, P. J., and Erneux, C. (1996) Biochem. Biophys. Res. Commun. 225, 243-249 [CrossRef][Medline] [Order article via Infotrieve]
  15. Jackson, S. P., Schoenwaelder, S. M., Matzaris, M., Brown, S., and Mitchell, C. A. (1995) EMBO J. 14, 4490-4500 [Abstract]
  16. Woscholski, R., Waterfield, M. D., and Parker, P. J. (1995) J. Biol. Chem. 270, 31001-31007 [Abstract/Free Full Text]
  17. Totty, N. F., Waterfield, M. D., and Hsuan, J. J. (1992) Protein Sci. 1, 1215-1224 [Abstract/Free Full Text]
  18. McPherson, P. S., Garcia, E. P., Slepnev, V. I., David, C., Zhang, X., Grabs, D., Sossin, W. S., Bauerfeind, R., Nemoto, Y., and De Camilli, C. P. (1996) Nature 379, 353-357 [CrossRef][Medline] [Order article via Infotrieve]
  19. Schu, P. V., Takegawa, K., Fry, M. J., Stack, J. H., Waterfield, M. D., and Emr, S. D. (1993) Science 260, 88-91 [Medline] [Order article via Infotrieve]
  20. Herman, P. K., and Emr, S. D. (1990) Mol. Cell. Biol. 10, 6742-6754 [Medline] [Order article via Infotrieve]
  21. Clague, M. J., Thorpe, C., and Jones, A. T. (1995) FEBS Lett. 367, 272-274 [CrossRef][Medline] [Order article via Infotrieve]
  22. Li, G., D'Souza Schorey, C., Barbieri, M. A., Roberts, R. L., Klippel, A., Williams, L. T., and Stahl, P. D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10207-10211 [Abstract]
  23. Shpetner, H., Joly, M., Hartley, D., and Corvera, S. (1996) J. Cell Biol. 132, 595-605 [Abstract]
  24. Clarke, J. F., Young, P. W., Yonezawa, K., Kasuga, M., and Holman, G. D. (1994) Biochem. J. 300, 631-635 [Medline] [Order article via Infotrieve]
  25. Kotani, K., Carozzi, A. J., Sakaue, H., Hara, K., Robinson, L. J., Clark, S. F., Yonezawa, K., James, D. E., and Kasuga, M. (1995) Biochem. Biophys. Res. Commun. 209, 343-348 [CrossRef][Medline] [Order article via Infotrieve]
  26. Matzaris, M., Jackson, S. P., Laxminarayan, K. M., Speed, C. J., and Mitchell, C. A. (1994) J. Biol. Chem. 269, 3397-3402 [Abstract/Free Full Text]
  27. Erneux, C., Lemos, M., Verjans, B., Vanderhaeghen, P., Delvaux, A., and Dumont, J. E. (1989) Eur. J. Biochem. 181, 317-322 [Abstract]
  28. Ramjaun, A. R., and McPherson, P. S. (1996) J. Biol. Chem. 271, 24856-24861 [Abstract/Free Full Text]
  29. Hug, H., and Sarre, T. F. (1993) Biochem. J. 291, 329-343 [Medline] [Order article via Infotrieve]
  30. Lee, S. B., and Rhee, S. G. (1995) Curr. Opin. Cell Biol. 7, 183-189 [CrossRef][Medline] [Order article via Infotrieve]
  31. Martys, J. L., Wjasow, C., Gangi, D. M., Kielian, M. C., McGraw, T. E., and Backer, J. M. (1996) J. Biol. Chem. 271, 10953-10962 [Abstract/Free Full Text]
  32. Arcaro, A., and Wymann, M. P. (1993) Biochem. J. 296, 297-301 [Medline] [Order article via Infotrieve]
  33. Woscholski, R., Kodaki, T., McKinnon, M., Waterfield, M. D., and Parker, P. J. (1994) FEBS Lett. 342, 109-114 [CrossRef][Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.